Pozen has filed another patent infringement lawsuit, as the Chapel Hill drug company fights to protect its portfolio of medicines from cheaper, copycat competitors.
Pozen and larger partner AstraZeneca filed the lawsuit in federal court in New Jersey, in an effort to block Dr. Reddy's Laboratories from selling a generic version of Vimovo.
Pozen and AstraZeneca won Food and Drug Administration approval to sell that drug as a treatment for arthritis pain a year ago. The companies contend the drug is protected by a patent that expires in 2023.
Last month, Dr. Reddy's notified the companies that it planned to seek FDA approval to market a generic version. Dr. Reddy's is one of India's biggest drug companies.